Approaching the era of personalised therapy for liver cancer?

The Lancet Oncology

Volumn 14, Issue 1, 2013, Pages 7-8

  Abou Alfa, Ghassan K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABOZANTINIB; GOLVATINIB; MET INHIBITOR; PLACEBO; PROTEIN KINASE INHIBITOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SORAFENIB; TIVANTINIB; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CONCENTRATION (PARAMETERS); HUMAN; LETTER; LIVER CELL CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT RESPONSE;

CARCINOMA, HEPATOCELLULAR; DRUG TOXICITY; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; PYRROLIDINONES; QUINOLINES;

EID: 84871719583     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70519-3     Document Type: Letter

References (10)

1. Cheng Y, Kang D, Lin J, et al. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2011, 29(suppl). for the SUN1170 HCC study group, abstr 4000.
2. Santoro A, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2012, published online Nov 20. http://dx.doi.org/10.1016/S1470-2045(12)70490-4.
3. Cohn AL, Kelley RK, Yang T-S, et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): Results from a phase II randomized discontinuation trial (RDT). Proc Am Soc Clin Oncol 2012, 30(suppl 4). abstr 261.
4. Llovet JM, Peña CE, Lathia CD, Shan M, Meinhardt G, Bruix J Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012, 18:2290-2300.
5. Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012, 57:821-829.
6. Huitzil D, Sun MY, Capanu M, et al. Expression of the c-met and HGF in resected hepatocellular carcinoma (rHCC): correlation with clinicopathological features (CP) and overall survival (OS). Proc Am Soc Clin Oncol 2008, 26(suppl). abstr 4599.
7. Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology 1997, 25:862-866.
8. Kaposi-Novak P, Lee JS, Gòmez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 2006, 116:1582-1595.
9. Ke AW, Shi GM, Zhou J, et al. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology 2009, 49:491-503.
10. Wang ZL, Liang P, Dong BW, Yu XL, Yu de J Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation: a retrospective study. J Gastrointest Surg 2008, 12:327-337.